Merck registers Phase 3 trial of Gocatamig with Durvalumab in small cell lung cancer
Merck Sharp & Dohme LLC has registered a Phase 3 randomized study to evaluate the safety and efficacy of Gocatamig (MK-6070) with Durvalumab versus Durvalumab alone as consolidation therapy in limited-stage small cell lung cancer. The trial plans to enroll 564 participants and is expected to start on December 7, 2026.
Primary source
ClinicalTrials.gov registry record, November 2, 2026
A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004)
Read the source: A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004) clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation